Can Brivaracetam be included in the scope of medical insurance reimbursement? Policy status analysis

Brivaracetam (Brivaracetam) is an anti-epileptic drug used to treat partial epilepsy. Because of its good efficacy and safety, it has attracted the attention of patients and doctors. However, Brivaracetam has not yet been officially launched in mainland China, which directly affects the possibility of medical insurance reimbursement. Due to the lack of domestic registration, patients cannot purchase the drug through domestic medical institutions and cannot enjoy medical insurance reimbursement.

Medical insurance reimbursement policies usually require that drugs must be approved by the National Medical Products Administration (NMPA) and included in the medical insurance catalog before medical insurance payment can be achieved. Brivaracetam has not yet received domestic approval and is therefore not eligible to be included in the medical insurance directory. This also means that even if the patient obtains Brivaracetam through special channels, the related costs cannot be reimbursed through medical insurance and must be paid entirely out of pocket, which increases the patient's financial burden.

In overseas markets, the original drug of Brivaracetam has been launched. The specifications are mostly 50mg*60 tablets, and the price is about 4000 multiple RMB. Although overseas drugs are more expensive, they are still an important treatment option for some patients. If patients need to use Brivaracetam, they usually need to purchase it through formal overseas channels. However, they should also pay attention to the legality and safety of the drug and avoid purchasing fake and shoddy products.

To sum up, Brivaracetam is currently not reimbursable by medical insurance in China. Patients need to carefully choose medication channels and be financially prepared. In the future, with the advancement of the domestic approval process and the accumulation of more clinical evidence, Brivaracetam is expected to be approved in China and entered into the medical insurance directory, bringing good news to more epilepsy patients. Patients should keep an eye on policy developments, communicate with their attending doctors in a timely manner, and formulate a reasonable treatment plan.

Reference materials:https://www.drugs.com